RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1

Nature

Volumn 498, Issue 7454, 2013, Pages 325-331

  Park, Jeehye ^a,b   Al Ramahi, Ismael ^a,b   Tan, Qiumin ^a,b   Mollema, Nissa ^c   Diaz Garcia, Javier R ^a,b   Gallego Flores, Tatiana ^a,b   Lu, Hsiang Chih ^a,b   Lagalwar, Sarita ^c   Duvick, Lisa ^c   Kang, Hyojin ^a,b,e   Lee, Yoontae ^a,b,f   Jafar Nejad, Paymaan ^a,b   Sayegh, Layal S ^a,b   Richman, Ronald ^a,b   Liu, Xiuyun ^a,b   Gao, Yan ^a,b   Shaw, Chad A ^a   Arthur, J Simon C ^d   Orr, Harry T ^c   Westbrook, Thomas F ^a   Botas, Juan ^a,b   Zoghbi, Huda Y ^a,b   more..

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e Korea Institute of Science and Technology Information (KISTI)   (South Korea)

^f Pohang University of Science and Technology (POSTECH)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 1; BIOLOGICAL MARKER; MITOGEN ACTIVATED PROTEIN KINASE; MSK1 PROTEIN; POLYGLUTAMINE; RAS PROTEIN; UNCLASSIFIED DRUG;

FLY; GENE EXPRESSION; INHIBITOR; NERVOUS SYSTEM DISORDER; NEUROLOGY; PATHOGENICITY; PROTEIN;

ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DOWN REGULATION; DROSOPHILA; GENETIC SCREENING; HUMAN; HUMAN CELL; INSECT GENETICS; MODULATION; MOUSE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SPINOCEREBELLAR DEGENERATION;

AMINO ACID SEQUENCE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DROSOPHILA MELANOGASTER; FEMALE; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN STABILITY; RAS PROTEINS; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SPINOCEREBELLAR ATAXIAS; TRANSGENES;

MUS;

EID: 84879414055     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12204     Document Type: Article

References (49)

1. Evans, D. A. Estimated prevalence of Alzheimer's disease in the United States. Milbank Q. 68, 267-289 (1990).
2. Hindle, J. V. Ageing, neurodegeneration and Parkinson's disease. Age Ageing 39, 156-161 (2010).
3. Marsden, C. D. & Parkes, J. D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1, 345-349 (1977).
4. Scarpini, E., Scheltens, P.& Feldman, H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol. 2, 539-547 (2003).
5. Ross, C. A. & Poirier, M. A. Protein aggregation and neurodegenerative disease. Nature Med. 10, S10-S17 (2004).
6. Taylor, J. P., Hardy, J. & Fischbeck, K. H. Toxic proteins in neurodegenerative disease. Science 296, 1991-1995 (2002).
7. Haass, C. & Selkoe,D. J.Solubleprotein oligomers inneurodegeneration: lessonsfrom the Alzheimer's amyloid b-peptide. Nature Rev. Mol. Cell Biol. 8, 101-112 (2007).
8. Zoghbi, H. Y. & Orr, H. T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217-247 (2000).
9. Singleton, A. B. et al. a-synuclein locus triplication causes Parkinson's disease. Science 302, 841 (2003).
10. Chartier-Harlin, M. C. et al. a-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169 (2004).
11. Rovelet-Lecrux, A. et al. APP locus duplication causes autosomal dominant earlyonset Alzheimer disease with cerebral amyloid angiopathy. Nature Genet. 38, 24-26 (2006).
12. Gö tz, J. & Ittner, L. M. Animal models of Alzheimer's disease and frontotemporal dementia. Nature Rev. Neurosci. 9, 532-544 (2008).
13. Williams, A. J. & Paulson, H. L. Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci. 31, 521-528 (2008).
14. Xia, H. et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nature Med. 10, 816-820 (2004).
15. Harper, S. Q. et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl Acad. Sci. USA 102, 5820-5825 (2005).
16. Yamamoto, A., Lucas, J. J. & Hen, R. Reversal of neuropathology andmotor dysfunctionina conditionalmodel ofHuntington's disease. Cell101, 57-66(2000).
17. Zu, T. et al. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J. Neurosci. 24, 8853-8861 (2004).
18. Kordasiewicz, H. B. et al. Sustained therapeutic reversal ofHuntington's disease by transient repression of huntingtin synthesis. Neuron 74, 1031-1044 (2012).
19. Zoghbi, H. Y. & Orr, H. T. Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J. Biol. Chem. 284, 7425-7429 (2009).
20. Emamian, E. S. et al. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 38, 375-387 (2003).
21. Noble, M. E., Endicott, J. A. & Johnson, L. N. Protein kinase inhibitors: insights into drug design from structure. Science 303, 1800-1805 (2004).
22. Fernandez-Funez, P. et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 408, 101-106 (2000).
23. Taniguchi, C. M., Emanuelli, B. & Kahn, C. R. Critial nodes in signalling pathways: insights into insulin action. Nature Rev. Mol. Cell Biol. 7, 85-96 (2006).
24. Shaharabany, M. et al. Distinct pathways for the involvement of WNK4 in the signaling of hypertonicity and EGF. FEBS J. 275, 1631-1642 (2008).
25. Teixeira-Castro, A. et al. Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by the DAF-16 and HSF-1 pathways. Hum. Mol. Genet. 20, 2996-3009 (2011).
26. Cobb, M. H. MAP kinase pathways. Prog. Biophys. Mol. Biol. 71, 479-500 (1999).
27. Avruch, J. Insulin signal transduction through protein kinase cascades. Mol. Cell. Biochem. 182, 31-48 (1998).
28. Al-Ramahi, I. et al. dAtaxin-2 mediates expanded Ataxin-1-induced neurodegeneration in a Drosophila model of SCA1. PLoS Genet. 3, e234 (2007).
29. Jorgensen, N. D. et al. Phosphorylation of ATXN1 at Ser776 in the cerebellum. J. Neurochem. 110, 675-686 (2009).
30. Roux, P. P. & Blenis, J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev. 68, 320-344 (2004).
31. Mody, N., Leitch, J., Armstrong, C., Dixon, J. & Cohen, P. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett. 502, 21-24 (2001).
32. Lackey, K. et al. The discovery of potent cRaf1 kinase inhibitors. Bioorg. Med. Chem. Lett. 10, 223-226 (2000).
33. Deak, M., Clifton, A. D., Lucocq, L. M. & Alessi, D. R. Mitogen-and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J. 17, 4426-4441 (1998).
34. Lorenzetti, D. et al. Repeat instability and motor incoordination in mice with a targeted expanded CAG repeat in the Sca1 locus. Hum. Mol. Genet. 9, 779-785 (2000).
35. Watase, K. et al. A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 34, 905-919 (2002).
36. Arthur, J. S. & Cohen, P.MSK1is required for CREB phosphorylation in response to mitogens in mouse embryonic stem cells. FEBS Lett. 482, 44-48 (2000).
37. Wiggin, G. R. et al. MSK1 and MSK2 are required for the mitogen-and stressinduced phosphorylation of CREB and ATF1 in fibroblasts. Mol. Cell. Biol. 22, 2871-2881 (2002).
38. Burright, E. N. et al. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82, 937-948 (1995).
39. Dar, A. C., Das, T. K., Shokat, K. M. & Cagan, R. L. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature 486, 80-84 (2012).
40. van Ham, T. J., Breitling, R., Swertz, M. A. & Nollen, E. A. Neurodegenerative diseases: lessons from genome-wide screens in small model organisms. EMBO Mol. Med. 1, 360-370 (2009).
41. Jeong, H. et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 137, 60-72 (2009).
42. Matsumoto, M. et al. Molecular clearance of ataxin-3 is regulated by a mammalian E4. EMBO J. 23, 659-669 (2004).
43. Cummings, C. J. et al. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 24, 879-892 (1999).
44. Chin, L. & Gray, J. W. Translating insights from the cancer genome into clinical practice. Nature 452, 553-563 (2008).
45. Falsig, J. & Aguzzi, A. The prion organotypic slice culture assay-POSCA. Nature Protocols 3, 555-562 (2008).
46. Jafar-Nejad, P., Ward, C. S., Richman, R., Orr, H. T. & Zoghbi, H. Y. Regional rescue of spinocerebellar ataxia type 1 phenotypes by 14-3-3 haploinsufficiency in mice underscores complex pathogenicity in neurodegeneration. Proc. Natl Acad. Sci. USA 108, 2142-2147 (2011).
47. Bowman, A. B. et al. Duplication of Atxn1l suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes. Nature Genet. 39, 373-379 (2007).
48. Lim, J. et al. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 452, 713-718 (2008).
49. Servadio, A. et al. Expression analysis of theataxin-1protein in tissues fromnormal and spinocerebellar ataxia type 1 individuals. Nature Genet. 10, 94-98 (1995).